Sinclair Pharma PLC Additional listing (9549A)
March 30 2017 - 2:02AM
UK Regulatory
TIDMSPH
RNS Number : 9549A
Sinclair Pharma PLC
30 March 2017
Sinclair Pharma plc
Additional listing
London, 30 March 2017 Sinclair Pharma plc (SPH.L), ("Sinclair"
or the "Company") the international aesthetics company, announces
that 1,570,510 new ordinary shares of 1p each (the "New Ordinary
Shares") have been issued and allotted to Christophe Foucher,
former COO, in settlement of his severance package as previously
announced on 1 September 2016.
Application will be made to the London Stock Exchange for the
New Ordinary Shares to be admitted to trading on AIM. Admission is
expected to be effective on 5 April 2017 and, when issued, the New
Ordinary Shares will rank pari passu in all respects with the
Company's existing ordinary shares.
Following admission of the New Ordinary Shares, Sinclair will
have 503,768,952 ordinary shares of 1p in issue.
This announcement contains inside information. The person
responsible for arranging for the release of this announcement on
behalf of Sinclair is Alan Olby, Chief Financial Officer.
For further information please contact:
Sinclair Pharma plc Tel: +44 (0)
20 7467 6920
Chris Spooner
Alan Olby
Andy Crane
Peel Hunt LLP (NOMAD Tel: +44 (0)
and Joint Broker) 20 7418 8900
James Steel
Oliver Jackson
RBC Capital Markets Tel: +44 (0)
(Joint Broker) 20 76534000
Marcus Jackson
Laura White
Media enquiries
FTI Consulting Tel: +44 (0)
203 727 1000
Ben Atwell
Brett Pollard
Notes to Editors:
About Sinclair Pharma plc
Sinclair Pharma plc is an international company operating in the
fast growth, high gross margin, global aesthetics market. Sinclair
has built a strong portfolio of differentiated, complementary
aesthetics technologies, which are experiencing significant growth,
targeting unmet clinical needs for effective, high quality, longer
duration, natural looking and minimally-invasive treatments. The
Company is planning entry to multiple new geographic markets and
line extension launches over the next few years. Sinclair has an
established sales and marketing presence in the leading EU markets
and Brazil, and a network of international distributors. For more
information, please visit www.sinclairpharma.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSDMGZFZLNGNZZ
(END) Dow Jones Newswires
March 30, 2017 02:02 ET (06:02 GMT)
Sinclair Pharma (LSE:SPH)
Historical Stock Chart
From Apr 2024 to May 2024
Sinclair Pharma (LSE:SPH)
Historical Stock Chart
From May 2023 to May 2024